Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 12/20 | 0.37 |
| ▸ | CDK4 | P11802 | 9/20 | 0.37 |
| ▸ | CTSK | P43235 | 5/20 | 0.37 |
| ▸ | CTSS | P25774 | 3/20 | 0.37 |
| ▸ | CDK2 | P24941 | 8/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 6/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.35 |
| ▸ | CDK9 | P50750 | 2/20 | 0.35 |
| ▸ | CCND3 | P30281 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15032374 | 0.78 | CDK4 (0.40) | CCND1CDK4CTSKCTSSCDK2 | |
| SCHEMBL6363390 | 0.77 | CTSK (0.48) | CCND1CDK4CTSKCTSSCDK2 | |
| SCHEMBL16625660 | 0.77 | AURKA (0.40) | CCND1CDK4CTSKCTSSCDK2 | |
| SCHEMBL20127004 | 0.76 | — | — | |
| SCHEMBL29651155 | 0.76 | MAT2A (0.33) | CCND1CDK4CCND3 | |
| SCHEMBL24267967 | 0.75 | — | — | |
| SCHEMBL4189989 | 0.75 | CCNT1 (0.42) | CCND1CDK4CTSKCTSSCDK2 | |
| SCHEMBL4200625 | 0.75 | KDM4E (0.31) | — | |
| SCHEMBL27927200 | 0.75 | NUAK1 (0.40) | CCND1CDK4CTSKCTSSCDK2 | |
| SCHEMBL28523935 | 0.74 | CDK4 (0.47) | CCND1CDK4CDK2CCNE1CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2026-05-28 | — | — | US | disclosed |
| CN-117720532-A | Pyrrolopyrimidine derivatives as RSK inhibitors and use thereof | 华东师范大学 | 2024-03-19 | — | — | CN | disclosed |
| US-20240043428-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LTD. (GB) | 2024-02-08 | — | — | US | disclosed |
| US-11111250-B2 | Polymorphs of Ribociclib mono succinate | SHILPA MEICARE LIMITED (IN) | 2021-09-07 | — | — | US | disclosed |
| US-20210253578-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LTD. (GB) | 2021-08-19 | — | — | US | disclosed |
| US-20210253578-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LTD. (GB) | 2021-08-19 | — | — | US | disclosed |
| US-20200339588-A1 | NOVEL POLYMORPHS OF RIBOCICLIB MONO SUCCINATE | SHILPA MEDICARE LIMITED (IN) | 2020-10-29 | — | — | US | disclosed |
| CN-108290899-B | Substituted pyrrolopyrimidine compound and application thereof | 深圳市塔吉瑞生物医药有限公司 | 2020-09-18 | — | — | CN | disclosed |
| US-20180155351-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2018-06-07 | — | — | US | disclosed |
| US-20180155351-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2018-06-07 | — | — | US | disclosed |
| WO-2011101417-A1 | DEUTERATED PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2011-08-25 | — | — | WO | disclosed |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| EP-2331547-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | Novartis AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| WO-2010020675-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | NOVARTIS AG (CH) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010020675-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | NOVARTIS AG (CH) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK9, CDK6, CDK7 | CCND1 57/4885CDK4 10/4885CTSK 2805/4885 |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | CCND1 46/4885CDK4 5/4885CTSK 1811/4885 |
| US-20200339588-A1 | NOVEL POLYMORPHS OF RIBOCICLIB MONO SUCCINATE | SUCLG2, RRM2B, SUCLA2 | CCND1 225/4885CDK4 85/4885CTSK 3705/4885 |
| US-20240043428-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | CCND1 46/4885CDK4 5/4885CTSK 1811/4885 |
| US-20180155351-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | CCND1 46/4885CDK4 5/4885CTSK 1811/4885 |
| US-20210253578-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | CCND1 46/4885CDK4 5/4885CTSK 1811/4885 |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | CCND1 46/4885CDK4 5/4885CTSK 1811/4885 |
| US-11111250-B2 | Polymorphs of Ribociclib mono succinate | SUCLG2, RRM2B, SUCLA2 | CCND1 311/4885CDK4 195/4885CTSK 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.